ALS United North Carolina is thrilled to announce that as a member of ALS United, we are now supporting the Accelerating Medicines Partnership (AMP) ALS Project, a groundbreaking initiative dedicated to accelerating ALS research and treatment development. Thanks to the generosity of our supporters, we’re taking significant steps towards finding effective treatments for ALS.
“AMP ALS launched in May 2024 with the aim to accelerate the development of validated biomarkers for early diagnosis and effective treatments, discover new therapeutic targets and improve clinical outcome assessments. The program will introduce a new centralized knowledge portal to enable collection, management and analysis of current and future ALS data, and expand accessibility to that data. Researchers will also explore standardizing clinical tools and including patient reported outcomes when assessing the efficiency and effectiveness of ALS treatments and clinical trials. People with lived experience of ALS, including individuals and families affected by the disease, caregivers, and those at high genetic risk for developing ALS in the future, participated in the development of the partnership, and will continue to be involved in this program.”
AMP ALS is part of the public-private partnership called for in H.R. 3537-Accelerating Access to Critical Therapies (ACT) for ALS Act, signed into law in December 2021.
To learn more, visit: https://www.ninds.nih.gov/current-research/focus-disorders/amyotrophic-lateral-sclerosis/accelerating-medicines-partnershipr-amyotrophic-lateral-sclerosis-ampr-als